JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M108080200 on October 18, 2001

J. Biol. Chem., Vol. 277, Issue 1, 719-724, January 4, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/1/719    most recent
M108080200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sasaki, Y.
Right arrow Articles by Tokino, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sasaki, Y.
Right arrow Articles by Tokino, T.

The p53 Family Member Genes Are Involved in the Notch Signal Pathway*

Yasushi SasakiDagger §, Setsuko IshidaDagger , Ichiro MorimotoDagger §, Toshiharu YamashitaDagger , Takashi Kojima, Chikashi Kihara||, Toshihiro Tanaka||, Kohzoh Imai§, Yusuke Nakamura||, and Takashi TokinoDagger **

From the Dagger  Department of Molecular Biology, Cancer Research Institute, § First Department of Internal Medicine, and  Department of Pathology, Sapporo Medical University School of Medicine, S-1, W-17, Chuo-ku, Sapporo, 060-8556 Japan and the || Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639 Japan

Received for publication, August 22, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The p53 tumor suppressor is a transcription factor that regulates cell growth and death in response to environmental stimuli such as DNA damage. p63/p51 and p73 were recently identified as members of the p53 gene family. In contrast to p53 however, p63 and p73 are rarely mutated in human cancers. Mice that lack p53 are developmentally normal, while p63 and p73 appear to play critical roles in normal development. To determine how p63 and p73 are involved in normal development, we attempted to identify target genes that are specifically regulated by p63 and/or p73 but not by p53. We found that the Jagged1 (JAG1) and Jagged2 (JAG2) genes, encoding ligands for the Notch receptors, are up-regulated by p63 and p73. Furthermore, we identified a p63-binding site in the second intron of the JAG1 gene, which can directly interact with the p63 protein in vivo, as assessed by a chromatin immunoprecipitation assay. A heterologous reporter assay revealed that this p63-binding site is a functional response element and is specific for p63. We also found a target of Notch signaling, HES-1 was up-regulated in Jurkat cells, in which Notch1 is highly expressed, when co-cultured with p63-transfected cells, suggesting that p63 can trigger the Notch signal pathway in neighboring cells. Our findings show an association between the p53 family genes and Notch signaling and suggest a potential molecular mechanism for the involvement of the p53 family genes in normal development.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The involvement of the p53 tumor suppressor gene in cell growth and death is mediated by the transactivation of p53-target genes in response to environmental stimuli such as DNA damage (1-3). p63/p51 and p73 were recently identified as members of the p53 gene family and encode proteins that share considerable structural homology with p53 (4-6). p63 and p73 can bind to the p53-responsive elements and up-regulate some p53-target genes, which suggest that the p53 family members have a potential for functional overlap with p53 itself (7-12). However, in contrast to p53, p63 and p73 are rarely mutated in human cancers (13-15).

Different phenotypes between p63- or p73-deficient and p53-deficient mice were also reported (16-19). In contrast to p53-deficient mice, mice lacking the p73 genes show no increased susceptibility to spontaneous tumorigenesis. p73-deficient mice have neurological, pheromonal and inflammatory defects. p63-deficient mice have major defects in their limbs and craniofacial development, as well as a striking absence of stratified epithelia, suggesting that p63 is required for limb and epidermal morphogenesis. In humans, Li-Fraumeni syndrome patients have inherited mutations of the p53 gene and develop normally, but are predisposed to cancer (20), while heterozygous germline mutations in the p63 gene are the cause of ectrodactyly, ectodermal dysplasia, and facial clefts syndrome (21). These studies demonstrate a marked divergence in the developmental roles of p63 and p73 and further distinguished these p53 family genes from p53. Despite these revelations, little is known about target genes specifically regulated by p63 or p73. Identifying the gene targets of p63 and p73 that play a role in development is an important step to a better understanding of the roles of these proteins in normal development and developmental disorders.

To determine what mediates the function of the p53 family members on normal development, we attempted to identify genes that are specifically regulated by p63 and/or p73 but not by p53. As a result, we identified the JAG1 and JAG2 genes as targets for p63 and p73. Thus, there are likely to be differences among the p53 family members with regard to their optimal DNA-binding sequences. We also showed p63-mediated JAG1 induction can activate Notch signaling in neighboring cells. This study is the first to implicate a link between the p53 family member genes and Notch signaling.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Lines and Recombinant Adenovirus-- The human cancer cell lines used in this study were purchased from American Type Culture Collection or the Japanese Collection of Research Bioresources (Osaka, Japan). All cell lines were cultured under conditions recommended by their respective depositors. The endogenous p53 statuses in these lines are wild type for A172 and HCT116, mutant for DLD1, colo320, and PLC/PRF5, and p53 null for Saos2 and H1299. The generation and purification of replication-deficient recombinant adenoviruses containing p53, p73alpha , p73beta , p63alpha , and p63gamma genes or the bacterial lacZ gene were described previously (11).

Immunoblot and Northern Blot Analysis-- The primary antibodies used in this study are as follows: mouse anti-human p53 monoclonal antibody (DO-7, Santa Cruz Biotechnology); mouse anti-human p73 monoclonal antibody (ER-15, Oncogene Research); mouse anti-human p63 monoclonal antibody (4A4, Oncogene Research); and rabbit anti-human JAG1 polyclonal antibody (H-114, Santa Cruz Biotechnology). For Northern blot analysis, total RNA (10 µg) was electrophoretically separated on a 1% agarose gel containing 2.2 M formaldehyde and blotted on a nitrocellulose membrane (Schleicher & Schuell). RNA was visualized with ethidium bromide to ensure that it was intact and loaded in similar amounts and to confirm proper transfer. Hybridization was performed as described previously (11). cDNA probes for JAG1 (nucleotides (nt)1 3531-4534), JAG2 (nt 419-1323), p21 (nt 11-429) and HES-1 (nt 286-642) were amplified by the reverse transcription-PCR from appropriate cDNA pools. PCR products were sequenced to verify their identity.

cDNA Microarray-- For cDNA expression arrays, poly(A)+ RNA was isolated with the FastTrack 2.0 mRNA isolation system (Invitrogen) from adenovirus-infected A172 human glioma cells and used as a template for synthesis of Cy3- or Cy5-labeled cDNA probes. The probes were hybridized to cDNA microarrays containing 9216 genes. Microarray construction, hybridization procedures, and data analysis were described previously (22, 23).

Immunofluorescence Microscopy-- Cells grown on glass coverslips were fixed in cold absolute acetone for 10 min. Following fixation, cells were washed in PBS then blocked in PBS plus 5% goat serum. Primary antibody (H-114) was diluted to 5 µg/ml in the presence of Triton X-100 and incubated for 2 h at room temperature. Cells were washed in PBS and then incubated with secondary antibody Alexa 488-conjugated goat anti-rabbit IgG (Molecular Probes) for 30 min at room temperature. The specimens were examined using a laser-scanning confocal microscope (MRC 1024; Bio-Rad).

Chromatin Immunoprecipitation Assay (ChIP)-- ChIP assay was performed using the Acetyl-Histone H3 ChIP Assay Kit (Upstate Biotechnology) as recommended by the manufacturer except that antibodies against p53 (DO-7), p63 (4A4), and FLAG tag peptide (M2, Sigma-Aldrich) were used in this study. 2 × 106 Saos2 cells were plated onto a 10-cm dish and infected with Ad-p53 or Ad-p63gamma . After 24 h, genomic DNA and protein were cross-linked by addition of formaldehyde (1% final concentration) directly to culture medium and incubated for 15 min at 37 °C. Cells were lysed in 200 µl of SDS lysis buffer with a protease inhibitor mixture and sonicated to generate 300-800 bp DNA fragments. After centrifugation, the cleared supernatant was diluted 10-fold with the ChIP dilution buffer and incubated with the specific antibody at 4 °C for 16 h. Immune complexes were precipitated, washed, and eluted as recommended. DNA-protein cross-links were reversed by heating at 65 °C for 5 h, and DNA was phenol-extracted, ethanol-precipitated, and resuspended in 50 µl of TE. Five microliters of each sample were used as a template for PCR amplification. PCR amplifications of the second intron of the JAG1 gene containing the consensus p53-binding sequences (+5597, renamed the RE-JAG1 sequence and +5983) were performed on immunoprecipitated chromatin using the specific primers 5'-ACCTTTCACCATTCCCCTAC-3' (forward) and 5'-GCCCAAGGACAAAATAGCCA-3' (reverse), and 5'-CCATTGTGCACAGTCAGTCG-3' (forward) and 5'-CCACTCGCATTGTGTGCATG-3' (reverse), respectively. PCR amplification of the p21 promoter was performed using oligonucleotides 5'-ACCTTTCACCATTCCCCTAC-3' (forward) and 5'-GCCCAAGGACAAAATAGCCA-3' (reverse), as described (24). To ensure that PCR was performed in linear range, template DNA was amplified for a maximum of 30 cycles. PCR products following ChIP assay were sequenced to verify the identity of the amplified DNA.

Luciferase Assay-- A 51-bp fragment of the RE-JAG1 (5'-AGGCTTCTTGTTCAGGCTTGCTCTGTGTGAACCAGACCGTTGTGCTTGGCT-3') and its mutant form (5'-AGGATTCTTGTTCAGGATTTCTCTGTGTGAAACATACCGTTGTGATTTGCT-3') were synthesized and inserted upstream of a basal SV40 promoter in the pGL3-promoter vector (Promega), and the resulting constructs were designated pGL3-RE-JAG1 and pGL3-RE-JAG1-mut, respectively. 1 × 106 of H1299 cells in 6-cm dishes were co-transfected with 1.5 µg of either pGL3-RE-JAG1 or pGL3-RE-JAG1-mut, together with 1.5 µg of a pcDNA3.1 control vector (Invitrogen) or a vector that expresses p53, p73beta , or p63gamma using Lipofectin (Life Technologies). Cells were harvested 48 h after transfection followed by measurement of luciferase activity using the Luciferase Assay System (Promega). The ability to stimulate transcription was defined as the ratio of luciferase activity in the cells transfected with the pGL3-RE-JAG1 relative to the activity in the cells transfected with the non-responsive reporter plasmid, pGL3-RE-JAG1-mut. As a control experiment, pGL3-p53CBS containing three copies of the consensus p53-binding sequence or its mutant form (11) were transfected into H1299 cells with a pcDNA3.1 control vector or a vector that expresses p53, p73beta , or p63gamma . All experiments were performed in triplicate and repeated on at least three independent occasions.

Co-culturing Assays-- Saos2 adherent cells (2 × 106) were incubated with purified virus at a m.o.i of 25. After 12 h, the cells were washed three times with medium, and overlaid with Jurkat non-adherent cells (3 × 106) in suspension. The co-cultures were incubated for 18 h, and Jurkat cells were harvested as described previously (25). Briefly, culture medium and unattached cells were removed from each plate, and the remaining cells were washed two times with PBS to harvest more tightly bound Jurkat cells. Total RNA was extracted from the Jurkat cells for Northern blotting analysis.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p63 and p73 Induce Expression of the JAG1 and JAG2 Genes-- To express the p53 family genes in human cancer cell lines, we used the replication-deficient adenoviral vector harboring human p53 (Ad-p53), p73beta (Ad-p73beta ), and p63gamma /p51A (Ad-p63gamma /Ad-p51A) genes. To determine the relative efficiency of adenovirus-mediated gene transfer, cells were infected with adenovirus containing the bacterial lacZ gene (Ad-lacZ). We used seven human cancer cell lines that showed highly efficient gene transfer, with 90-100% of the cells staining for beta -galactosidase activity at a m.o.i. of 50-100. A high-level p53 protein was observed in cells infected with Ad-p53 (examples in Fig. 1, upper panel). Infection with Ad-p73beta and Ad-p63gamma resulted in expression of exogenous p73beta and p63gamma proteins, respectively (examples in Fig. 1, middle and lower panels). We used p73beta and p63gamma /p51A isoforms in this study because we and others have demonstrated that transcription of a p53-responsive reporter gene was activated more strongly in p73beta and p63gamma /p51A than p73alpha and p63alpha /p51B (5, 11, 26).


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 1.   Expression of p53, p73beta , and p63gamma after adenoviral infection in A172, DLD1, and Saos2 cells. Cells were infected with adenoviruses at a m.o.i. of 50 or 100 and were harvested at 24 h following infection. Immunoblot analysis was performed on lysates (5 µg) from cells infected with Ad-lacZ (lanes 1, 5, and 9), Ad-p53 (lanes 2, 6 and 10), Ad-p73beta (lanes 3, 7, and 11) and Ad-p63gamma (lanes 4, 8, and 12).

In an effort to identify specific targets regulated by p73 and p63, we performed cDNA microarray analysis and compared expression patterns in a human glioma cell line A172 transfected separately with Ad-p53, Ad-p73beta , and Ad-p63gamma . Using this approach, we detected several genes that were reproducibly activated in p73- and p63-transfected cells but not in p53-transfected cells. Two of the genes that were selectively induced by p63 and p73 were JAG1 and JAG2. Northern blot analysis using the JAG1 and JAG2 cDNAs as probes demonstrated that expression of the JAG1 gene was dramatically increased by infection with Ad-p63gamma and Ad-p73beta in a time-dependent manner, but not by infection with Ad-p53 (Fig. 2). The JAG1 induction was seen as early as 9 h after Ad-p63gamma infection, similar to induction of p21, a well defined target for both p53 and its family members (Fig. 2) (1, 4, 6). The early induction of JAG1 suggests that the JAG1 gene may be a direct target of transcriptional activation by p73 and p63.


View larger version (46K):
[in this window]
[in a new window]
  		Fig. 2.   Time course of JAG1 and JAG2 induction following adenovirus-mediated transfer of p63 and p73 in A172 human glioma cells. A172 cells were infected with adenoviruses at a m.o.i. of 50, and the cells were harvested at the indicated times following infection. Total RNA were extracted and subjected to Northern blotting. Total RNA (10 µg) were loaded in each lane, and the same filter was re-hybridized with human JAG1, JAG2, and p21 cDNAs. Ethidium bromide staining of 28 S ribosomal RNA (28S) in the lower panel shows that equal amounts of RNA were loaded in each lane.

To investigate whether JAG1 induction by p73 and p63 is specific to the cell-type used, we performed Northern blot analysis with seven human cancer cell lines, including DLD1, colo320, and HCT116 (colorectal cancers), Saos2 (osteogenic sarcoma), H1299 (lung cancer), PLC/PRF5 (hepatocellular carcinoma), and A172 (glioma) (Fig. 3). JAG1 was highly induced by p63gamma and by p73beta in six of seven lines tested (no induction in PLC/PRF5 cells). In contrast, JAG1 induction by p53 was less dramatic and occurred in only three cell lines (DLD1, Saos2, and colo320 cells). JAG1 expression was reduced by p53 in H1299 and HCT116 cells. In addition, we examined JAG1 expression after infection with Ad-p73alpha and Ad-p63alpha /p51B in A172 and DLD1 cells (Fig. 3A). p73alpha was the strongest activator of JAG1 in A172 cells. JAG2 was highly induced by p73beta in all seven cell lines tested (Fig. 3), though at a later time point relative to JAG1 (Fig. 2). JAG2 was also induced by p63gamma in six of seven cell lines (Fig. 3, second panel). In the majority of cell lines tested, the strongest induction of JAG1 and JAG2 were observed following Ad-p63gamma and Ad-p73beta infection, respectively (Fig. 3). Ad-p53 induction of p21 was observed in all seven lines, but Ad-p63gamma and Ad-p73beta induced p21 only in a subset of these lines (Fig. 3, third panel).


View larger version (63K):
[in this window]
[in a new window]
  		Fig. 3.   Northern blot analysis shows JAG1 and JAG2 induction in human cancer cell lines. Seven human cancer cell lines were infected with adenoviruses at a m.o.i. of 50 or 100. Ten µg of total RNA isolated 24 h after infection was subjected to Northern blotting.

We then examined the level of JAG1 protein by Immunoblot analysis using an antibody against the intracellular domain of human JAG1. Fig. 4A shows the high-level accumulation of endogenous JAG1 protein in Ad-p63gamma -infected Saos2 cells and Ad-p73beta - and Ad-p63gamma -infected A172 cells, consistent with the Northern blot analysis (Fig. 3). Immunofluorescence staining using the same antibody also verified the expression of endogenous JAG1 in Ad-p63gamma -infected Saos2 cells but not in control or Ad-lacZ-infected cells. The subcellular distribution of JAG1 coincided with that reported previously (27). In contrast, Ad-p53 infection resulted in only a slight increase in JAG1 expression (Fig. 4B). To determine whether expression of other Notch ligands and receptors are regulated by the p53 family genes, Northern blot analysis was performed. Neither Notch ligands (DLL1, DLL3, DLL4) nor Notch receptors (Notch1, Notch2, Notch3, Notch4) were significantly induced by p73, p63, or p53 in A172 and DLD1 cells (data not shown).


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 4.   The endogenous JAG1 protein is increased by transfection of Ad-p63 or Ad-p73. A, immunoblot analysis was performed on cell lysates from A172 and Saos2 cells 24 h following infection with Ad-lacZ (lanes 1 and 5), Ad-p53 (lanes 2 and 6), Ad-p73beta (lanes 3 and 7), or Ad-p63gamma (lanes 4 and 8). Cell extracts (30 µg) were separated by electrophoresis on a 10% SDS/acrylamide gel and analyzed by Western blotting using the JAG1 C-terminal antibody H-114. B, immunofluorescence analysis of JAG1 protein expression of control Saos2 cells (a) and Saos2 cells 24 h following infection with Ad-lacZ (b), Ad-p53 (c), or Ad-p63gamma (d) is shown. Cells were stained with the JAG1 C-terminal antibody H-114. Omission of the primary antibody resulted in no staining (data not shown).

Identification of a Specific Target Sequence for p63 in the JAG1 Gene-- The early and strong induction of JAG1 suggests that JAG1 may be a direct and specific target of transcriptional activation by p63. To address this hypothesis, we searched for a consensus p53-binding sequence in the JAG1 gene because the p63 and p73 proteins can also bind to the p53-binding sites (4-7, 28). We obtained the genomic sequence of the human JAG1 gene from the GenBankTM data base (accession number AL035456) and searched for a consensus p53-binding site(s) within 10 kb in and around exon 1 of the JAG1 gene. Ten candidate sequences were identified at the positions -5162, -3133, -2098, -1555, -1131, +2814, +5597, +5983, +7637, and +8102, where +1 represents the translation initiation site.

To determine whether the p63 protein can selectively bind to any of these candidate binding sites in vivo, we performed ChIP assays. The ChIP assay relies on the ability of specific antibodies to immunoprecipitate DNA-binding proteins along with the associated genomic DNA. We used Saos2 cells infected with either Ad-p53 or Ad-p63gamma for ChIP assay, since the induction of JAG1 by p63gamma was strongest in this line (Figs. 3 and 4). Immunoprecipitation of DNA-protein complex using antibodies against p53 and p63 was performed on formaldehyde-cross-linked extract from Ad-p53- and Ad-p63gamma -infected Saos2 cells, respectively. We then measured the abundance of candidate sequences within the immunoprecipitate complexes by PCR. ChIP assay revealed that one DNA fragment containing a candidate sequence, +5597, was reproducibly present in a complex with p63gamma protein (Fig. 5B, middle panel, lane 3). We designated this p63-binding sequence RE-JAG1 (for responsive element in JAG1). RE-JAG1 consists of four copies of the consensus 10-bp motif separated by 3, 5, and 3 bp, respectively (Fig. 5A). In contrast, p53 protein binding to RE-JAG1 sequence was not detectable in p53-infected cells, as assessed by the ChIP assay with an anti-p53 antibody and subsequent PCR (Fig. 5B, middle panel, lane 6). The other nine candidates were amplified in the input-positive control for PCR, but not in the immunoprecipitated samples with an antibody against p53 or p63 (examples in Fig. 5B, lower panel). As a positive control for the ChIP assay, we analyzed the interaction of p53 and p63 with the p21 promoter. Both p53 and p63 proteins immunoprecipitated with the DNA fragment containing the p53-binding site in the p21 promoter (Fig. 5B, upper panel, lanes 3 and 6). Although we can not exclude a low level of p53 binding to the RE-JAG1 sequence, our ChIP data indicate that p63 is selectively associated with this site in vivo.


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 5.   Regulation of JAG1 expression by p63. A, schematic representation of part of the JAG1 gene. A potential responsive site, RE-JAG1, is located at the second intron of the JAG1 gene and consists of four copies of the consensus 10-bp motif of the p53-binding sequence. Lowercase letters identify disparities with the consensus. R represents purine; Y, pyrimidine; and W, adenine or thymidine. B, p63 interacts with the RE-JAG1 sequence in vivo. ChIP assay of a genomic fragment (nucleotide position +5499 to +5749, where +1 represents the translation initiation site) containing the RE-JAG1 sequence in Ad-p63gamma -infected (lanes 3-5) or Ad-p53-infected (lanes 6-8) Saos2 cells is shown (middle panel). Immunoprecipitation was performed using the gene-specific antibody against p63 (lane 3) or p53 (lane 6), followed by PCR amplification. Input chromatin represents a portion of the sonicated chromatin prior to immunoprecipitation (lanes 1 and 2). Immunoprecipitates with an anti-FLAG antibody (lanes 4 and 7) or in the absence of antibody (no antibody, lanes 5 and 8) were used for controls. DW indicates a no template control (lane 9). PCR amplification of the p21 promoter was performed using primers that flank the p53-binding site in the p21 promoter. PCR amplification revealed that a similar amount of p21 promoter sequence is present in p53- and p63-complexes extracted from each immunoprecipitate (upper panel). The RE-JAG1 was amplified in the immunoprecipitated samples with an antibody against p63 (middle panel, lane 3). One of the other candidate sequences, +5983, is amplified in the input control, but not in the immunoprecipitated samples with an antibody against p53 or p63 (lower panel). C, the RE-JAG1 in the JAG1 gene is responsive to p63gamma . H1299 cells were co-transfected with pGL3-RE-JAG1 or pGL3-RE-JAG1-mut, together with the expression vector pcDNA3.1 containing the p53, p73beta , or p63gamma gene. The relative luciferase activity was defined as the ratio of luciferase activity in the cells transfected with the pGL3-RE-JAG1 relative to the activity in cells transfected with the non-responsive reporter plasmid, pGL3-RE-JAG1-mut. As a control experiment, pGL3-p53CBS containing three copies of the consensus p53-binding sequence (p53CBS × 3) or its mutant form was transfected into H1299 cells with the expression vector containing p53, p73beta , or p63gamma . All experiments were performed in triplicate and the means and standard deviation are indicated by the bars and brackets, respectively.

To determine whether RE-JAG1 possesses p63-dependent transcriptional activity, we performed a heterologous promoter-reporter assay using a luciferase vector prepared by cloning the oligonucleotide corresponding to RE-JAG1 sequence upstream of a basal SV40 promoter (see "Experimental Procedures"). A control reporter plasmid, pGL3-RE-JAG1-mut, was generated by altering potentially critical nucleotides of the RE-JAG1 sequence. H1299 cells were transiently co-transfected with pGL3-RE-JAG1 or pGL3-RE-JAG1-mut together with a p53, p73beta , or p63gamma -expressing plasmid. The ability to stimulate transcription was calculated as the luciferase activity in cells transfected with the pGL3-RE-JAG1 divided by the activity in cells transfected with the non-responsive reporter plasmid, pGL3-RE-JAG1-mut. Fig. 5C shows that the increase in luciferase activity for pGL3-RE-JAG1 was higher for p63gamma than for either p53 or p73beta . These results are consistent with the strong induction of endogenous JAG1 by p63gamma (Fig. 3). As a control, we demonstrate that the level of transcription from a reporter, pGL3-p53CBS, containing three copies of the p53 consensus binding sequence was higher for p53 than for p63 or p73 (Fig. 5C). Taken together, our results suggest that there are likely to be differences among the p53 family members with regard to their optimal DNA-binding sequences and that RE-JAG1 is a functional p63-responsive element.

p63 Leads to the Activation of the Notch Signal Pathway-- The extracellular domain of Notch is thought to interact with a ligand expressed on neighboring cells. Recent in vitro studies have shown that exogenously applied Notch ligands can activate endogenous Notch signal pathway (29-31). Thus, we tested whether the JAG1 induction mediated by p63 or p73 could promote a functional interaction with cells expressing endogenous Notch1 receptor. The gene encoding the mammalian transcription factor HES-1 is a direct downstream target of the Notch signal pathway (32). As Notch1 has been reported to be highly expressed in Jurkat cells (25, 33, 34), we examined whether HES-1 mRNA was up-regulated in Jurkat cells co-cultured with Ad-p63gamma -infected Saos2 cells. HES-1 mRNA was not detectable in Ad-p63gamma -infected Saos2 cells (Fig. 6, lane 1). In Jurkat cells, HES-1 mRNA was up-regulated 3-fold by co-culturing with Ad-p63gamma -infected Saos2 cells compared with co-culturing with control Ad-lacZ-infected cells (Fig. 6, lane 6). In contrast, expression of p53 or p73beta in Saos2 cells exhibited only slight HES-1 induction in co-cultured Jurkat cells (Fig. 6, lanes 4 and 5). The simplest interpretation of these data is that p63gamma -induced JAG1 expression triggered Notch signaling in neighboring Jurkat cells.


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 6.   Functional interaction between p63gamma -expressing Saos2 cells and Jurkat cells. HES-1 mRNA was analyzed by Northern blotting with Ad-p63gamma -infected Saos2 cells (lane 1), control Jurkat cells (lane 2), or Jurkat cells co-cultured on monolayers of adenoviral-infected Saos2 cells for 18 h (lanes 3-6). Total RNA (10 µg) were loaded in each lane. Endogenous HES-1 expression in Jurkat cells was increased 3-fold by co-culturing with Ad-p63gamma -infected Saos2 cells relative to co-culture with control Ad-lacZ-infected cells (lane 6).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Two members of the mammalian p53 family, p73 and p63, encode proteins that share considerable structural homology with p53, suggesting that the p53 family members have a potential for functional overlap. Indeed, the expression of several p53-regulated genes can also be induced by p73 and p63, though recent studies show considerable differences of inducibility among p53 and its family members (8, 10, 12). In this study, Northern blot analysis revealed that JAG1 and JAG2 expression are preferentially induced by p63gamma and p73beta , respectively. Induction of JAG1 and JAG2 was seen following ectopic expression of p63 or p73 in various types of human cancer cell lines regardless of p53 status. Additionally, JAG1 induction was considerably high and early relative to that of p21. We identified a specific binding site for p63 in the second intron of the JAG1 gene by a ChIP assay. A reporter assay demonstrated that the p63-binding site, RE-JAG1, was important for the p63-dependent transactivation. RE-JAG1 consists of four copies of the 10-bp p53-binding motif. Characterization of the responsive sequence for p73 within the promoter of AQP3 (35) and the p73 gene itself (36) was described in two recent studies. Both responsive sequences consist of three copies of the 10-bp p53-binding motif. We also showed that ectopic expression of p73beta strongly induced JAG2 expression in all cell lines tested. It remains to be elucidated whether the JAG2 expression is controlled directly by p73. Altogether, our findings clearly indicate that JAG1 is a direct target for p63 and possibly for p73.

The Notch family of transmembrane receptors has been reported to play an important role in development by specifying cell fates (37, 38). To date, five Notch ligands have been identified, including JAG1, JAG2, Delta like-1 (DLL1), DLL3, and DLL4, all of which are transmembrane proteins having an extracellular domain important for receptor binding (39-43). Here we demonstrated physical but also functional involvement of p63 in the Notch/Jagged signal pathway. The induction of JAG1 correlated with the initiation of signaling downstream of the Notch receptor in co-cultivated cells. Endogenous HES-1 expression was up-regulated in Notch1-expressing Jurkat cells by co-culturing with Ad-p63gamma -infected Saos2 cells. This agrees with a recent report showing that Rel/NFkappa B-mediated JAG1 expression can transactivate endogenous HES-1 gene expression in co-cultured Jurkat cells (25). Our findings indicate that p63 can trigger the Notch signal pathway in the neighboring cells and therefore raise the possibility that the members of the p53 family play a role in normal development through modulating Notch signal pathway.

Ligand-mediated activation of Notch induces the proteolytic release of the intracellular domain of Notch and transactivation of its target genes, which leads to modulation of cell proliferation and differentiation (44, 45). Mutations in human Notch ligands result in the disruption of the Notch signal pathway, leading to developmental abnormalities (46-48). Mutations in the JAG1 gene have been found in patients with Alagille syndrome, an autosomal dominant disorder characterized by abnormal development of heart, skeleton, liver, and eye, as well as a characteristic facial appearance. Our data are generally consistent with the similarity between the developmental defects associated with alteration in the p53 family members and those of Notch ligands (17-19, 21, 46-49). In particular, JAG2-deficient mice exhibit defects of limb and craniofacial development (49), closely resembling the phenotype of patients with ectrodactyly, ectodermal dysplasia, and facial clefts syndrome, in which p63 is mutated. Both p63 and p73 can transactivate the promoters of genes associated with neuronal or epidermal differentiation, and overexpression of these genes up-regulates neuronal or epidermal differentiation markers (50, 51). Together with our findings, these studies highlight the potential for an interplay between the p53 family genes and Notch signal pathway during ectodermal development.

In conclusion, we report that Notch ligands, JAG1 and JAG2, are selectively induced by p73 and p63, respectively, but not by p53. We also identified a specific binding site for the p63 protein in the second intron of the JAG1 gene and showed that p63 can activate Notch signaling to the neighboring cells. Our findings point to a potential role for p63 and p73 in normal development and cellular regulation mediated by Notch signaling.

    ACKNOWLEDGEMENT

We thank Dr. Joseph F. Costello for critical comments about this manuscript.

    FOOTNOTES

* This research was supported in part by grants-in-aid for cancer research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Dept. of Molecular Biology, Cancer Research Inst., Sapporo Medical Univ. School of Medicine, S-1, W-17, Chuo-ku, Sapporo, 060-8556 Japan. Tel.: 81-11-611-2111 Ext. 2410; Fax: 81-11-618-3313; E-mail: tokino@sapmed.ac.jp.

Published, JBC Papers in Press, October 18, 2001, DOI 10.1074/jbc.M108080200

    ABBREVIATIONS

The abbreviations used are: nt, nucleotides; PBS, phosphate-buffered saline; ChIP, chromatin immunoprecipitation assay; m.o.i., multiplicity of infection.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. el-Deiry, W. S. (1998) Semin. Cancer Biol. 8, 345-357[CrossRef][Medline] [Order article via Infotrieve]
2. Tokino, T., and Nakamura, Y. (2000) Crit. Rev. Oncol. Hematol. 33, 1-6[Medline] [Order article via Infotrieve]
3. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Nature 408, 307-310[CrossRef][Medline] [Order article via Infotrieve]
4. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. (1997) Cell 90, 809-819[CrossRef][Medline] [Order article via Infotrieve]
5. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. (1998) Mol. Cell. 2, 305-316[CrossRef][Medline] [Order article via Infotrieve]
6. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. (1998) Nat. Med. 4, 839-843[CrossRef][Medline] [Order article via Infotrieve]
7. Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. (1997) Nature 389, 191-194[CrossRef][Medline] [Order article via Infotrieve]
8. Zhu, J., Jiang, J., Zhou, W., and Chen, X. (1998) Cancer Res. 58, 5061-5065[Abstract/Free Full Text]
9. Di Como, C. J., Gaiddon, C., and Prives, C. (1999) Mol. Cell. Biol. 19, 1438-1449[Abstract/Free Full Text]
10. Shimada, A., Kato, S., Enjo, K., Osada, M., Ikawa, Y., Kohno, K., Obinata, M., Kanamaru, R., Ikawa, S., and Ishioka, C. (1999) Cancer Res. 59, 2781-2786[Abstract/Free Full Text]
11. Ishida, S., Yamashita, T., Nakaya, U., and Tokino, T. (2000) Jpn. J. Cancer Res. 91, 174-180[CrossRef][Medline] [Order article via Infotrieve]
12. Levrero, M., De, Laurenzi, V., Costanzo, A., Gong, J., Wang, J. Y., and Melino, G. (2000) J. Cell Sci. 113, 1661-1670[Abstract]
13. Mai, M., Huang, H., Reed, C., Qian, C., Smith, J. S., Alderete, B., Jenkins, R., Smith, D. I., and Liu, W. (1998) Genomics 51, 359-363[CrossRef][Medline] [Order article via Infotrieve]
14. Ichimiya, S., Nimura, Y., Kageyama, H., Takada, N., Sunahara, M., Shishikura, T., Nakamura, Y., Sakiyama, S., Seki, N., Ohira, M., Kaneko, Y., McKeon, F., Caput, D., and Nakagawara, A. (1999) Oncogene 18, 1061-1066[CrossRef][Medline] [Order article via Infotrieve]
15. Irwin, M. S., and Kaelin, W. G., Jr. (2001) Apoptosis 6, 17-29[CrossRef][Medline] [Order article via Infotrieve]
16. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., and Bradley, A. (1992) Nature 356, 215-221[CrossRef][Medline] [Order article via Infotrieve]
17. Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., and McKeon, F. (1999) Nature 398, 714-718[CrossRef][Medline] [Order article via Infotrieve]
18. Mills, A. A., Zheng, B., Wang, X. J., Vogel, H., Roop, D. R., and Bradley, A. (1999) Nature 398, 708-713[CrossRef][Medline] [Order article via Infotrieve]
19. Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., McKeon, F., and Caput, D. (2000) Nature 404, 99-103[CrossRef][Medline] [Order article via Infotrieve]
20. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al.. (1990) Science 250, 1233-1238[Abstract/Free Full Text]
21. Celli, J., Duijf, P., Hamel, B. C., Bamshad, M., Kramer, B., Smits, A. P., Newbury-Ecob, R., Hennekam, R. C., Van Buggenhout, G., van Haeringen, A., Woods, C. G., van Essen, A. J., de Waal, R., Vriend, G., Haber, D. A., Yang, A., McKeon, F., Brunner, H. G., and van Bokhoven, H. (1999) Cell 99, 143-153[CrossRef][Medline] [Order article via Infotrieve]
22. Ono, K., Tanaka, T., Tsunoda, T., Kitahara, O., Kihara, C., Okamoto, A., Ochiai, K., Takagi, T., and Nakamura, Y. (2000) Cancer Res. 60, 5007-5011[Abstract/Free Full Text]
23. Okabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y., and Nakamura, Y. (2001) Cancer Res. 61, 2129-2137[Abstract/Free Full Text]
24. Shaulian, E., Schreiber, M., Piu, F., Beeche, M., Wagner, E. F., and Karin, M. (2000) Cell 103, 897-907[CrossRef][Medline] [Order article via Infotrieve]
25. Bash, J., Zong, W. X., Banga, S., Rivera, A., Ballard, D. W., Ron, Y., and Gelinas, C. (1999) EMBO J. 18, 2803-2811[CrossRef][Medline] [Order article via Infotrieve]
26. Prabhu, N. S., Somasundaram, K., Satyamoorthy, K., Herlyn, M., and El-Deiry, W. S. (1998) Int. J. Oncol. 13, 5-9[Medline] [Order article via Infotrieve]
27. Morrissette, J. D., Colliton, R. P., and Spinner, N. B. (2001) Hum. Mol. Genet. 10, 405-413[Abstract/Free Full Text]
28. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1, 45-49[CrossRef][Medline] [Order article via Infotrieve]
29. Jarriault, S., Le, Bail, O., Hirsinger, E., Pourquie, O., Logeat, F., Strong, C. F., Brou, C., Seidah, N. G., and Israel, A. (1998) Mol. Cell. Biol. 18, 7423-7431[Abstract/Free Full Text]
30. Sestan, N., Artavanis-Tsakonas, S., and Rakic, P. (1999) Science 286, 741-746[Abstract/Free Full Text]
31. Hicks, C., Johnston, S. H., diSibio, G., Collazo, A., Vogt, T. F., and Weinmaster, G. (2000) Nat. Cell Biol. 2, 515-520[CrossRef][Medline] [Order article via Infotrieve]
32. Jarriault, S., Brou, C., Logeat, F., Schroeter, E. H., Kopan, R., and Israel, A. (1995) Nature 377, 355-358[CrossRef][Medline] [Order article via Infotrieve]
33. Ellisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., and Sklar, J. (1991) Cell 66, 649-661[CrossRef][Medline] [Order article via Infotrieve]
34. Aster, J., Pear, W., Hasserjian, R., Erba, H., Davi, F., Luo, B., Scott, M., Baltimore, D., and Sklar, J. (1994) Cold Spring Harb. Symp. Quant. Biol. 59, 125-136[Medline] [Order article via Infotrieve]
35. Zheng, X., and Chen, X. (2001) FEBS Lett. 489, 4-7[CrossRef][Medline] [Order article via Infotrieve]
36. Chen, X., Zheng, Y., Zhu, J., Jiang, J., and Wang, J. (2001) Oncogene 20, 769-774[CrossRef][Medline] [Order article via Infotrieve]
37. Weinmaster, G. (1997) Mol. Cell Neurosci. 9, 91-102[CrossRef][Medline] [Order article via Infotrieve]
38. Artavanis-Tsakonas, S., Rand, M. D., and Lake, R. J. (1999) Science 284, 770-776[Abstract/Free Full Text]
39. Lindsell, C. E., Shawber, C. J., Boulter, J., and Weinmaster, G. (1995) Cell 80, 909-917[CrossRef][Medline] [Order article via Infotrieve]
40. Shawber, C., Boulter, J., Lindsell, C. E., and Weinmaster, G. (1996) Dev. Biol. 180, 370-376[CrossRef][Medline] [Order article via Infotrieve]
41. Bettenhausen, B., Hrabe de Angelis, M., Simon, D., Guenet, J. L., and Gossler, A. (1995) Development 121, 2407-2418[Abstract]
42. Dunwoodie, S. L., Henrique, D., Harrison, S. M., and Beddington, R. S. (1997) Development 124, 3065-3076[Abstract]
43. Shutter, J. R., Scully, S., Fan, W., Richards, W. G., Kitajewski, J., Deblandre, G. A., Kintner, C. R., and Stark, K. L. (2000) Genes Dev. 14, 1313-1318[Abstract/Free Full Text]
44. Struhl, G., and Adachi, A. (1998) Cell 93, 649-660[CrossRef][Medline] [Order article via Infotrieve]
45. Schroeter, E. H., Kisslinger, J. A., and Kopan, R. (1998) Nature 393, 382-386[CrossRef][Medline] [Order article via Infotrieve]
46. Oda, T., Elkahloun, A. G., Pike, B. L., Okajima, K., Krantz, I. D., Genin, A., Piccoli, D. A., Meltzer, P. S., Spinner, N. B., Collins, F. S., and Chandrasekharappa, S. C. (1997) Nat. Genet. 16, 235-242[CrossRef][Medline] [Order article via Infotrieve]
47. Li, L., Krantz, I. D., Deng, Y., Genin, A., Banta, A. B., Collins, C. C., Qi, M., Trask, B. J., Kuo, W. L., Cochran, J., Costa, T., Pierpont, M. E., Rand, E. B., Piccoli, D. A., Hood, L., and Spinner, N. B. (1997) Nat. Genet. 16, 243-251[CrossRef][Medline] [Order article via Infotrieve]
48. Bulman, M. P., Kusumi, K., Frayling, T. M., McKeown, C., Garrett, C., Lander, E. S., Krumlauf, R., Hattersley, A. T., Ellard, S., and Turnpenny, P. D. (2000) Nat. Genet. 24, 438-441[CrossRef][Medline] [Order article via Infotrieve]
49. Jiang, R., Lan, Y., Chapman, H. D., Shawber, C., Norton, C. R., Serreze, D. V., Weinmaster, G., and Gridley, T. (1998) Genes Dev. 12, 1046-1057[Abstract/Free Full Text]
50. De Laurenzi, V., Raschella, G., Barcaroli, D., Annicchiarico-Petruzzelli, M., Ranalli, M., Catani, M. V., Tanno, B., Costanzo, A., Levrero, M., and Melino, G. (2000) J. Biol. Chem. 275, 15226-15231[Abstract/Free Full Text]
51. De Laurenzi, V., Rossi, A., Terrinoni, A., Barcaroli, D., Levrero, M., Costanzo, A., Knight, R. A., Guerrieri, P., and Melino, G. (2000) Biochem. Biophys. Res. Commun. 273, 342-346[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
Y. Sasaki, Y. Oshima, R. Koyama, R. Maruyama, H. Akashi, H. Mita, M. Toyota, Y. Shinomura, K. Imai, and T. Tokino
Identification of Flotillin-2, a Major Protein on Lipid Rafts, as a Novel Target of p53 Family Members
Mol. Cancer Res., March 1, 2008; 6(3): 395 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. B. Truong, M. Kretz, T. W. Ridky, R. Kimmel, and P. A. Khavari
p63 regulates proliferation and differentiation of developmentally mature keratinocytes.
Genes & Dev., November 15, 2006; 20(22): 3185 - 3197.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
S. Ichimiya and T. Kojima
Cellular Networks of Human Thymic Medullary Stromas Coordinated by p53-Related Transcription Factors
J. Histochem. Cytochem., November 1, 2006; 54(11): 1277 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. J. Krieg, E. M. Hammond, and A. J. Giaccia
Functional Analysis of p53 Binding under Differential Stresses.
Mol. Cell. Biol., October 1, 2006; 26(19): 7030 - 7045.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. M. Caserta, R. Kommagani, Z. Yuan, D. J. Robbins, C. A. Mercer, and M. P. Kadakia
p63 Overexpression Induces the Expression of Sonic Hedgehog
Mol. Cancer Res., October 1, 2006; 4(10): 759 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
B.-C. Nguyen, K. Lefort, A. Mandinova, D. Antonini, V. Devgan, G. Della Gatta, M. I. Koster, Z. Zhang, J. Wang, A. T. di Vignano, et al.
Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation
Genes & Dev., April 15, 2006; 20(8): 1028 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
J. Laurikkala, M. L. Mikkola, M. James, M. Tummers, A. A. Mills, and I. Thesleff
p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation
Development, April 15, 2006; 133(8): 1553 - 1563.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Osada, H. L. Park, Y. Nagakawa, K. Yamashita, A. Fomenkov, M. S. Kim, G. Wu, S. Nomoto, B. Trink, and D. Sidransky
Differential Recognition of Response Elements Determines Target Gene Specificity for p53 and p63
Mol. Cell. Biol., July 15, 2005; 25(14): 6077 - 6089.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Saifudeen, V. Diavolitsis, J. Stefkova, S. Dipp, H. Fan, and S. S. El-Dahr
Spatiotemporal Switch from {Delta}Np73 to TAp73 Isoforms during Nephrogenesis: IMPACT ON DIFFERENTIATION GENE EXPRESSION
J. Biol. Chem., June 17, 2005; 280(24): 23094 - 23102.
[Abstract] [Full Text] [PDF]

Home page
 GENES CELLSHome page
N. Matsushita, Y. Takami, M. Kimura, S. Tachiiri, M. Ishiai, T. Nakayama, and M. Takata
Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells
Genes Cells, April 1, 2005; 10(4): 321 - 332.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-i. Kurata, T. Okuyama, M. Osada, T. Watanabe, Y. Tomimori, S. Sato, A. Iwai, T. Tsuji, Y. Ikawa, and I. Katoh
p51/p63 Controls Subunit {alpha}3 of the Major Epidermis Integrin Anchoring the Stem Cells to the Niche
J. Biol. Chem., November 26, 2004; 279(48): 50069 - 50077.
[Abstract] [Full Text] [PDF]

Home page
 Carcinogenesis